Tri Locum Partners’s United Therapeutics UTHR Stock Holding History

Tri Locum Partners’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25.5M	Sell	47,026 -23,344	-33%	-$13.1M	3.13%	12
2026 Q1	$41.7M	Sell	70,370 -50,551	-42%	-$25.2M	5.86%	9
2025 Q4	$58.9M	Sell	120,921 -1,266	-1%	-$590K	7.65%	4
2025 Q3	$51.2M	Buy	+122,187	New	+$41.1M	11.77%	2
2024 Q4	–	Sell	-54,926	Closed	-$19.7M	–	32
2024 Q3	$19.7M	Buy	54,926 +4,826	+10%	+$1.63M	4.72%	9
2024 Q2	$16M	Buy	+50,100	New	+$13.3M	4.04%	14
2022 Q1	–	Sell	-45,904	Closed	-$9.92M	–	49
2021 Q4	$9.92M	Buy	45,904 +13,053	+40%	+$2.56M	3.91%	11
2021 Q3	$6.06M	Buy	+32,851	New	+$6.47M	2.41%	17

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Tri Locum Partners's UTHR Position: Q2 2026 in Review

Tri Locum Partners reduced its United Therapeutics (UTHR) stake by 33% in Q2 2026, selling an estimated $13.1M and leaving 47,026 shares worth $25.5M. The position accounts for 3.13% of the portfolio, ranked #12.

Tri Locum Partners first reported a position in UTHR in Q3 2021 and has held it in 8 quarters since. The position peaked at $58.9M in Q4 2025. 879 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Tri Locum Partners held 47,026 shares of United Therapeutics worth $25.5M as of Q2 2026.
Tri Locum Partners sold 23,344 United Therapeutics shares in Q2 2026, an estimated $13.1M.
United Therapeutics made up 3.13% of Tri Locum Partners's portfolio in Q2 2026, its #12 holding.
Tri Locum Partners first reported a position in United Therapeutics in Q3 2021 and has held it in 8 quarters since.
Tri Locum Partners's United Therapeutics position peaked at $58.9M in Q4 2025.
879 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Tri Locum Partners's 13F filing for Q2 2026, filed 14 Aug 2026.